Q-omics provides the consensus-scored ERN2 profile across patient tissues and cancer cell-line models. ERN2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ERN2 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, ERN2 RNA expression shows 14,460 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, LUAD, and ESCA as cancer lineages where ERN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERN2 survival associations across molecular data types. ERN2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERN2 RNA expression–survival associations across cancer types. High ERN2 expression shows unfavorable associations in UVM, KIRC and LGG, but favorable associations in HNSC, SCLC and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ERN2 RNA expression.
This table summarizes ERN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ERN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERN2 shows lower tumor expression in HNSC and PRAD and higher tumor expression in LUAD, THCA, PAAD and STAD. The LUAD box plot shows higher ERN2 RNA expression in tumor versus normal tissue (log2 FC = +1.034, t-test p < 0.001).
This table shows molecular features associated with ERN2 in patient tissues and cancer cell lines. In patient samples, ERN2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ERN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
